Related Experiment Video
Updated: May 26, 2026
08:19
Solid Lipid Nanoparticles (SLNs) for Intracellular Targeting Applications
Published on: November 17, 2015
siRNA delivery with lipid-based systems: promises and pitfalls
1Department of Pharmaceutics and Analytical Chemistry, Faculty of Pharmaceutical Sciences, University of Copenhagen, Universitetsparken 2, DK-2100 Copenhagen, Denmark. cfo@farma.ku.dk
Current Topics in Medicinal Chemistry
|December 27, 2011
Summary
Lipid-based carriers show promise for delivering small interfering RNA (siRNA) therapeutics, but challenges remain in achieving safe and effective in vivo delivery. Further research into cellular delivery mechanisms is crucial for optimizing these RNA interference (RNAi) systems.
Area of Science:
- Biotechnology
- Nanomedicine
- Pharmacology
Background:
- RNA interference (RNAi) therapeutics, such as small interfering RNA (siRNA), face significant delivery challenges for clinical application.
- Lipid-based carriers offer versatile properties for siRNA protection, targeting, and cellular uptake.
- Current lipidic systems for siRNA delivery exhibit limitations including in vivo efficacy, toxicity, and immunogenicity.
Purpose of the Study:
- To review the constituents of lipid-based siRNA carriers.
- To discuss recent advancements in improving cellular delivery of siRNA.
- To highlight challenges in immune activation and side effects, and propose solutions.
Main Methods:
- Literature review of lipid-based siRNA delivery systems.
- Analysis of mechanisms for cellular interaction, internalization, and intracellular transport.
- Discussion of immunogenicity and toxicity associated with lipidic carriers.
Main Results:
- Lipid-based carriers are widely used for siRNA delivery, often employing cationic lipids for complexation.
- Improvements in lipidic systems focus on enhancing cellular entry and endosomal escape.
- Significant challenges persist regarding in vivo delivery efficiency and immune system stimulation.
Conclusions:
- Optimizing lipidic siRNA delivery requires a deeper understanding of cellular interactions and intracellular trafficking.
- Addressing toxicity and immune responses is critical for the clinical translation of RNAi therapeutics.
- Further research into tailored lipid formulations can overcome current delivery hurdles.
Related Concept Videos
01:24Site-Targeted Drug Delivery Systems: Polymeric Carriers
Polymeric carriers enhance targeted drug delivery by increasing efficacy while minimizing off-target effects. These carriers comprise a biodegradable polymeric backbone integrated with functional elements that enable targeting, improve physicochemical properties, and regulate drug release.Targeting MechanismsThe targeting ability of polymeric carriers is mediated by a homing device, which is a molecular recognition component designed to selectively bind to specific tissues or cells. Monoclonal...
01:24Modified-Release Drug Delivery Systems: Site-Targeted
Site-targeted drug delivery systems enhance therapeutic efficacy while minimizing systemic toxicity and treatment costs. Unlike conventional methods, these systems ensure precise drug delivery, improving bioavailability and reducing side effects. Targeted drug delivery is classified into three levels. First-order targeting directs drugs to the capillary beds of specific organs or tissues. Second-order targets specific cell types, such as tumor cells, using receptor-mediated interactions.
01:16Drug Delivery: Overview
The selection of a drug's delivery route depends upon its physicochemical properties, including lipid or water solubility and ionization, as well as the therapeutic requirement, such as immediate or sustained effect. These routes can be divided into three primary categories: enteral, parenteral, and topical.
Enteral delivery involves administering drugs directly through swallowing, sublingual placement, or buccal application. Orally administered drugs predominantly navigate the gastrointestinal...
Enteral delivery involves administering drugs directly through swallowing, sublingual placement, or buccal application. Orally administered drugs predominantly navigate the gastrointestinal...
01:19Modified-Release Drug Delivery Systems: Overview
Modified-release dosage forms are designed to address the limitations of drugs with short biological half-lives. These forms maintain stable therapeutic drug concentrations over extended periods, reducing the need for frequent dosing. A consistent drug level helps minimize peak-trough fluctuations, which can reduce adverse effects, lower the risk of drug resistance, and improve overall treatment effectiveness.One common type of modified-release form is the extended-release (ER) formulation. ER...
01:27Drug Delivery Systems: Different Types
Conventional oral drug products, termed immediate-release (IR) formulations, are engineered to promptly release their active pharmaceutical ingredient (API) upon ingestion, typically in tablets or capsules. This rapid release often results in swift drug absorption and consequent pharmacodynamic effects, although the timing and intensity can vary depending on the drug's properties. Prodrugs within these formulations require metabolic conversion to activate their pharmacodynamic effects,...
01:27Bioavailability Enhancement: Drug Permeability Enhancement
After oral administration, poor permeability often limits the rate at which drugs are absorbed through the intestinal epithelium. Enhancing drug permeability is crucial for effective therapy, and several strategies have been developed to overcome this challenge.One effective strategy involves the use of lipid-based formulations. These formulations enhance dissolution and solubility, targeting physiological mechanisms to increase drug absorption. This includes stimulating bile salt secretion,...